Mirum Pharmaceuticals to Participate in Upcoming Investor Conferences
-
Morgan Stanley 22nd Annual Global Healthcare Conference
-
Company presentation -
Wednesday, September 4 th starting at8:30 a.m. ET
-
Company presentation -
-
H.C. Wainwright 26th AnnualGlobal Investment Conference onTuesday, September 10 th -
Baird 2024 Global Healthcare Conference on
Wednesday, September 11 th -
2024
Cantor Global Healthcare Conference -
Company presentation -
Wednesday, September 18 th starting at1:55 p.m. ET
-
Company presentation -
Visit the Investors and Media section of Mirum’s corporate website for webcast links and additional information.
About
LIVMARLI, an IBAT inhibitor, is approved for the treatment of two rare liver diseases affecting children and adults. It is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome in the
Mirum’s late-stage pipeline includes three investigational treatments for debilitating liver diseases. LIVMARLI is currently being evaluated in the Phase 3 EXPAND study in additional settings of cholestatic pruritus. Volixibat, an IBAT inhibitor, is being evaluated in two potentially registrational studies including the Phase 2 VISTAS study for primary sclerosing cholangitis (PSC) and Phase 2b VANTAGE study for primary biliary cholangitis. Lastly, chenodiol, has been evaluated in a Phase 3 clinical study, RESTORE, to treat patients with CTX, with positive topline results reported in 2023. Mirum has submitted a new drug application with the FDA for the approval of chenodiol to treat CTX in the
To learn more about Mirum, visit mirumpharma.com and follow Mirum on Facebook, LinkedIn, Instagram and Twitter (X).
View source version on businesswire.com: https://www.businesswire.com/news/home/20240828258017/en/
Investor Contacts:
ir@mirumpharma.com
Media Contact:
media@mirumpharma.com
Source: